Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical PerspectivesPaul Willner Cambridge University Press, 1991 M02 21 - 540 pages Much of psychopharmacology is concerned with the use of animal behavior to model aspects of human psychiatric disorders. Even so, behavioral models in psychopharmacology are used for different purposes; the main concern of industrial psychopharmacologists is specifically to develop new and improved drugs for the treatment of mental disorders, while research scientists use animal models to investigate the underlying nature of such conditions. The important distinction between these different perspectives is made explicit for the first time in this book. By considering such conditions as anxiety, depression, mania and schizophrenia, feeding disorders, dementia, and drug dependence, this book provides a comprehensive and critical review of the adequacy of the behavioral procedures used by psychopharmacologists to model psychiatric disorders. |
From inside the book
Results 1-5 of 91
Page v
... Psychology City of London Polytechnic , London , England The right of the University of Cambridge to print and sell all manner of books was granted by Henry VIII in 1534 . The University has printed and published continuously since 1584 ...
... Psychology City of London Polytechnic , London , England The right of the University of Cambridge to print and sell all manner of books was granted by Henry VIII in 1534 . The University has printed and published continuously since 1584 ...
Page vi
... . 3. Drug Screening . 4. Models , Psychological . 5. Psychotropic Drugs- pharmacology . QV 77 B4185 ] RM315.B367 1991 616.89'18 - dc20 90-1779 CIP ISBN 0 521 39192 X hardback CE For Matthew and Jessica X 251 XIII 253 1 3.
... . 3. Drug Screening . 4. Models , Psychological . 5. Psychotropic Drugs- pharmacology . QV 77 B4185 ] RM315.B367 1991 616.89'18 - dc20 90-1779 CIP ISBN 0 521 39192 X hardback CE For Matthew and Jessica X 251 XIII 253 1 3.
Page x
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page xi
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page 4
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Contents
XIII | 253 |
3 | 311 |
N Stephens and John S Andrews | 359 |
Strategies for drug development in | 419 |
Paul Willner | 437 |
J F W Deakin | 453 |
Animal models of eating disorders | 485 |
a clinical | 503 |
521 | |
Common terms and phrases
5-HT receptor action activity aged agonists Alzheimer's disease amphetamine animal models antagonists antidepressant drugs antipsychotic anxiolytic Archives assess associated Bartus basal benzodiazepine biochemical Biochemistry and Behavior body weight Brain Research British Journal buspirone catecholamine cholecystokinin cholinergic chronic clinical clonidine cocaine cognitive compounds conditioned cortical deficits dementia dependence discrimination disorders dopamine doses eating effects endogenous Experimental factors feeding fenfluramine food intake forebrain function GABA haloperidol hippocampus human hyperactivity imipramine impairments increased induced inhibitors injection interaction involved Iversen Journal of Pharmacology Journal of Psychiatry learned helplessness lesions lithium mania mechanisms memory mice model of depression models of anxiety monkeys naloxone neurochemical neuroleptics neurons Neuroscience neurotransmitter nucleus obesity opiate paradigm passive avoidance patients Pharmacology physiological physostigmine potential procedure Psychology Psychopharmacology rats Raven Press receptor reduced reinforcement response schizophrenia Science scopolamine self-administration serotonin social specific stimulation studies suggested symptoms syndrome therapeutic treatment tricyclic Willner withdrawal York